Hanmi Pharmaceutical announced on Jan. 30 that it sold 153 billion won worth of hypertension drugs last year, ranking first in this segment of the Korean drug market. The company's high blood pressure drug lineup consists of 15 products.
The Korean hypertension drug market stood at 1,835 billion won as of 2019, with Hanmi Pharmaceutical accounting for 8.3 percent.
The company's high blood pressure medications range from generics to improved and composite new drugs such as the Amosartan Family (Amosartan, Amosartan Q, Amosartan Plus), Rovelito, Osartan, Torssem, and Carberol.
The sales growth of the Amosaltan Family, which was developed by Hanmi Pharmaceutical, significantly contributed to putting Hanmi Pharm into the first spot in Korea's hypertension market.
In 2019, Amosartan, which was launched 10 years ago, posted 74.1 billion won in revenue (an year-on year increase of 10 percent) and Amosartan Plus stood out with 18.2 billion won in revenue and an 84 percent increase from 2018 based on UBIST data.
Hanmi Pharm's anti-high blood pressure drugs continue to enjoy success in the global market. MSD exports Amosartan to more than 10 countries under the brand name of Coza XQ, while Mexico's Silanes is taking steps to localize Amosartan Plus and Amosartan Q in Mexico.